+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2019

  • ID: 4900147
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 75 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adamed Sp zoo
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Lb Pharmaceuticals Inc
  • Praeventix LLC
  • MORE
5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2019

Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 2, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Genetic Disorders, Male Health, Respiratory and Women's Health which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Autism, Cognitive Disorders, Psychiatric Disorders, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Crohn's Disease (Regional Enteritis), Female Sexual Dysfunction, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Male Sexual Dysfunction, Neuropathic Pain (Neuralgia), Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders, Social Anxiety Disorder (SAD/Social Phobia) and Ulcerative Colitis.

The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2019, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adamed Sp zoo
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Lb Pharmaceuticals Inc
  • Praeventix LLC
  • MORE
Introduction
Report Coverage
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
Adamed Sp zoo
Avineuro Pharmaceuticals Inc
Daya Drug Discoveries Inc
H. Lundbeck AS
Johnson & Johnson
Lb Pharmaceuticals Inc
Praeventix LLC
Reviva Pharmaceuticals Inc
Seropeutics LLC
Sumitomo Dainippon Pharma Co Ltd
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-18038683 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5 HT7 Receptors for Crohn’s Disease and Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vortioxetine hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
Featured News & Press Releases
Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
Sep 20, 2019: Takeda and Lundbeck’s Trintellix approved in Japan for depression
Sep 03, 2019: Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China
Jul 31, 2019: Sumitomo Dainippon Pharma submits New Drug Application for approval of Manufacturing and Marketing for Lurasidone in Japan for the treatment of Schizophrenia and Bipolar Depression
Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmonary fibrosis
May 02, 2019: Sunovion highlights data on LATUDA at the 2019 American Psychiatric Association Annual Meeting
Jan 29, 2019: Sumitomo Dainippon Pharma announces the approval of atypical antipsychotic Latuda (lurasidone HCl) for the treatment of patients with schizophrenia in China
Jan 10, 2019: Sumitomo Dainippon Pharma announces positive topline results from a phase III clinical study (JEWEL Study) of Lurasidone, an atypical antipsychotic agent, in the treatment of patients with schizophrenia
Dec 05, 2018: Sumitomo Dainippon Pharma announces resolution of consolidated patent infringement lawsuit regarding ANDAs for LATUDA in the U.S.
Nov 27, 2018: Sumitomo Dainippon Pharma announces resolution of disputes under consolidated patent infringement lawsuit regarding ANDAs for LATUDA in the U.S.
Oct 22, 2018: U.S. Food and Drug Administration approves expansion of Trintellix (vortioxetine) label
Oct 22, 2018: New Data Added to TRINTELLIX (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
Sep 28, 2018: Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
Jun 08, 2018: Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
May 02, 2018: TRINTELLIX (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adamed Sp zoo, H2 2019
Pipeline by Avineuro Pharmaceuticals Inc, H2 2019
Pipeline by Daya Drug Discoveries Inc, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Lb Pharmaceuticals Inc, H2 2019
Pipeline by Praeventix LLC, H2 2019
Pipeline by Reviva Pharmaceuticals Inc, H2 2019
Pipeline by Seropeutics LLC, H2 2019
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adamed Sp zoo
  • Avineuro Pharmaceuticals Inc
  • Daya Drug Discoveries Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Lb Pharmaceuticals Inc
  • Praeventix LLC
  • Reviva Pharmaceuticals Inc
  • Seropeutics LLC
  • Sumitomo Dainippon Pharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll